The claim
“HHS should consider using march-in rights when drugs face limited competition or market practices have failed to ensure an affordable price, ensuring that prescription drugs invented with taxpayer dollars are reasonably priced and affordable.”
Sources and attribution
Original review: Washington Post. Structured data compiled by Data Commons under CC BY 4.0. Publisher article content is subject to its own terms.
Updated